In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3027-3034

  Kim, Jin C ^a,b   Shin, Eui S ^a   Kim, Chan W ^a,b   Roh, Seon A ^a,b   Cho, Dong H ^a,b   Na, Young S ^a,b   Kim, Tae W ^a,b   Kim, Moon B ^b   Hyun, Young L ^b   Ro, Seonggu ^b   Kim, Seon Y ^b,c   Kim, Yong S ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Korean Research Institute for Bioscience and Biotechnology   (South Korea)

Author keywords

Chemosensitivity; Colorectal adenocarcinomas; Combination; Histone deacetylase inhibitor; In vitro assay

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CG 2; FLUOROURACIL; FOLINIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IRINOTECAN; OXALIPLATIN; PROTEIN P53; UNCLASSIFIED DRUG; VORINOSTAT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68649122684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. National Comprehensive Cancer Network®: NCCN clinical practice guidelines in oncology. Colon and rectal cancer. v.1.2008, www.nccn.org.
2. Sabharwal A and Kerr D: Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther 7: 477-487, 2007. (Pubitemid 46681804)
3. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH and D'Angelica M: Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14: 1151-1160, 2007.
4. Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M and Ritchie JW: The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60: 275-283, 2007. (Pubitemid 46742543)
5. BurgessA, RuefliA, Beamish H, Warrener R, Saunders N, Johnstone R and Gabrielli B: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23: 6693-6701, 2004. (Pubitemid 39280001)
6. Glaser KB: HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.
7. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM and Duvic M: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115, 2007. (Pubitemid 47218059)
8. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS and Cheson BD: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large B-cell lymphoma. Ann Oncol 19: 964-969, 2008. (Pubitemid 351298334)
9. Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M, Akagi Y and Shirouzu K: Elevated preoperative serum carcinoembryonic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol 99: 65-70, 2009.
10. Strassburg CP: Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9: 703-715, 2008.
11. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y and Nozawa S: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15: 445-452, 2005. (Pubitemid 40705539)
12. Meng H, Tanigawa N, Hao CY, Dai DJ, Lu CD and Ji JF: Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer. Hepatogastroenterology 54: 1934-1940, 2007.
13. Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, Yamamoto M, Tsujikawa K, Kitazono M, Ishizawa T, Takeuchi T, Aikou T, Mercer JF, Akiyama S and Furukawa T: Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 67: 4860-4868, 2007. (Pubitemid 46910194)
14. Khan O and La Thangue NB: Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 5: 714-726, 2008.
15. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS and Lee JS: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24: 209-218, 2009.
16. Mass R: The development of Avastin. In: Tumor Angiogenesis Marmé D and Fuseni N (eds.). Berlin, Springer, pp. 611-654, 2008
17. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH and Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1987.
18. Kim JC, Han MS, Lee HK, Kim WS, Park SK, Park KC, Bodmer WF, Rowan AJ and Kim OJ: Distribution of carcinoembryonic antigen and biologic behavior in colorectal carcinoma. Dis Colon Rectum 42: 640-648, 1999.
19. Samson DJ, Seidenfeld J, Ziegler K and Aronson N: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630, 2004. (Pubitemid 41103669)
20. Yan L, Hsu K and Beckman RA: Antibody-based therapy for solid tumors. Cancer J 14: 178-183, 2008.
21. Marchion D and Münster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7: 583-598, 2007. (Pubitemid 46690964)
22. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL and Blanke CD: Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs, in press, 2009.
23. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ and Belani CP: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13: 3605-3610, 2007. (Pubitemid 46955122)
24. Eskens FA and Sleijfer S: The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 44: 2350-2356, 2008.
25. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S and Cree IA: Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs 14: 369-375, 2003. (Pubitemid 36683749)
26. Fakhrejahani E, Miyamoto A and Tanigawa N: Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother Pharmacol 60: 437-446, 2007. (Pubitemid 46950623)
27. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24: 3245-3251, 2006.
28. cip1/wafl. Int J Biochem Cell Biol 39: 1367-1374, 2007. (Pubitemid 47031035)
29. Bouali S, Chrétien AS, Ramacci C, Rouyer M, Marchal S, Galenne T, Juin P, Becuwe P and Merlin JL: P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther 16: 498-507, 2009.
30. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Gottlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463, 2004. (Pubitemid 38610247)
31. Kaler P, Sasazuki T, Shirasawa S, Augenlicht L and Klampfer L: HDAC2 deficiency sensitizes colon cancer cells to TNFα-induced apoptosis through inhibition of NF-κB activity. Exp Cell Res 314: 1507-1518, 2008.
32. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K and Yamada Y: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5: 2185-2191, 1999. (Pubitemid 29399276)
33. Pignatelli M, Durbin H and Bodmer WF: Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. Proc Natl Acad Sci USA 87: 1541-1545, 1990. (Pubitemid 20080344)
34. Tokunaga N, Kijima H, Noto T, Osamura Y, Sadahiro S, Tajima T and Mitomi T: Immunohistochemical localization of carcinoembryonic antigen as a predictor of lymph node status in submucosa-invasive colorectal carcinoma. Dis Colon Rectum 38: 842-847, 1995.
35. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C and Galizia G: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100: 270-278, 2004. (Pubitemid 38063634)
36. Ergün S, Kilik N, Ziegeler G, Hansen A, Nollau P, Götze J, Wurmbach JH, Horst A, Weil J, Fernando M and Wagener C: CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 5: 311-320, 2000. (Pubitemid 30628089)
37. Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ and Reed MW: The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut 56: 1426-1432, 2007.
38. b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98: 1366-1379, 2008. (Pubitemid 351543576)